Authors: Saba N.; Khuri F.

Source: Expert Opinion on Investigational Drugs, Volume 13, Number 6, 1 June 2004 , pp. 609-629(21)

Publisher: Informa Healthcare

Abstract:

Lung cancer is the leading cause of cancer-related mortality in the US. Although an improvement in outcome is possible with the continued advancement of cytotoxic-based treatment, clinical research is currently focused on utilising novel molecular targets with proven efficacy in preclinical models and a low toxicity profile. This is the result of advances in understanding of tumour biology and molecular pathways that have been implicated in cancer pathogenesis and progression. Novel agents targeting cell cycle regulation, angiogenesis and signal transduction pathways have reached clinical testing in lung cancer and are discussed in this review.

Keywords: angiogenesis; cyclooxygenase; epidermal growth factor; farnesyl transferase; gene therapy; lung cancer; targeted therapy; vaccine therapy

Document Type: Review article

DOI: http://dx.doi.org/10.1517/13543784.13.6.609

Publication date: 2004-06-01

More about this publication?

• Editorial Board
• Information for Authors
• Subscribe to this Title
• Terms & Conditions
• ingentaconnect is not responsible for the content or availability of external websites

Related content

• In this: publication
• By this: publisher
• In this Subject: Pharmacology
• By this author: Saba N. ;  Khuri F.

Website © Publishing Technology. Article copyright remains with the publisher, society or author(s) as specified within the article.

• Terms and conditions
• Privacy policy
• Information for advertisers